KCL-286

Overview

KCL-286 (C286) is an orally active and brain-penetrant retinoic acid receptor (RAR) β2 agonist ( EC 50 = 1.9 nM). KCL-286 targets RARβ2 with good selectivity over RAR α (EC 50 = 26 nM) and RAR γ (EC 50 = 11 nM). KCL-286 activates RARβ2 in the injured neurons. KCL-286 induces axonal regeneration of both spinal and sensory nerves through the inhibitory environment of the CNS, modulates neuroinflammation and extracellular matrix molecules. KCL-286 can modulate the expression of CSPGs by neuronal secretion of decorin which promotes myelination and aids axonal growth. KCL-286 can be studied in research for area such as spinal cord injury and traumatic nerve injury.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Others | Products > Signaling Pathways > RAR/RXR

Product Information

• Catalog No.: HY-111573
• CAS No.: 1952276-71-9
• Molecular Formula: C19H14N2O4
• Molecular Weight: 334.33
• Purity: 98.93%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 0.62 mg/mL (1.85 mM); Clear solution
• Availability: In-stock

Source

Original product source